Novartis presented the histology data of iscalimab in patients underwent transplantation

Novartis presented the histology data of iscalimab in the patients who underwent kidney transplantation. The study is showing the durability and long-term benefits with iscalimab in the patients who underwent kidney transplantation.

Iscalimab is a monoclonal antibody. Mechanism of action includes inhibiting cluster of differentiation 40 (CD40) pathway signaling and activation of CD40+ cell types

The data was presented at the American Transplant Congress. The efficacy of iscalimab compared with tacrolimus by using chronic allograft damage index, 60% of patients shown normal histological data in the iscalimab arm compared to none on tacrolimus arm.